BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29633481)

  • 1. Osteosarcoma mimic in the breast: A recurrent malignant phyllodes tumour harbouring MED12 and hTERT mutations.
    Tokoyoda M; Adachi S; Ishida Y; Yamazaki K
    Cytopathology; 2018 Aug; 29(4):383-385. PubMed ID: 29633481
    [No Abstract]   [Full Text] [Related]  

  • 2. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
    Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent MED12 mutations in phyllodes tumours of the breast.
    Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
    Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MED12 exon 2 mutations in phyllodes tumors of the breast.
    Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
    Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
    Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
    J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of a targeted gene mutation panel in refining the diagnosis of breast phyllodes tumours.
    Koh VCY; Ng CCY; Bay BH; Teh BT; Tan PH
    Pathology; 2019 Aug; 51(5):531-534. PubMed ID: 31272781
    [No Abstract]   [Full Text] [Related]  

  • 11. Local recurrence of a phyllodes tumour of the breast presenting with widespread differentiation to a telangiectatic osteosarcoma.
    Graadt van Roggen JF; Zonderland HM; Welvaart K; Peterse JL; Hogendoorn PC
    J Clin Pathol; 1998 Sep; 51(9):706-8. PubMed ID: 9930079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periductal Stromal Tumor of the Breast with a
    Anderson B; Marotti JD; Lefferts JA; Muller KE
    Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
    Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
    J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Diagnostic Approach to Fibroepithelial Breast Lesions.
    Tan BY; Tan PH
    Surg Pathol Clin; 2018 Mar; 11(1):17-42. PubMed ID: 29413655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.
    Yoon N; Bae GE; Kang SY; Choi MS; Hwang HW; Kim SW; Lee JE; Nam SJ; Gong G; Lee HJ; Bae YK; Lee A; Cho EY
    Genes Chromosomes Cancer; 2016 Jun; 55(6):495-504. PubMed ID: 26856273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
    Lien HC; Huang CS; Yang YW; Jeng YM
    Histopathology; 2016 Feb; 68(3):433-41. PubMed ID: 26109290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant phyllodes tumors of the breast: A comprehensive literature review.
    Papas Y; Asmar AE; Ghandour F; Hajj I
    Breast J; 2020 Feb; 26(2):240-244. PubMed ID: 31478587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
    Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
    Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.